
The medical AI debate needs a failure plan, not a bigger promise
AdvaMed's response to the FDA raises a useful buying question: what happens when a medical AI system is wrong, changes or encounters an unfamiliar case?
THE VITALNEX EDIT
Thoughtful reporting, useful context, and ideas for a more connected everyday.
2 stories

AdvaMed's response to the FDA raises a useful buying question: what happens when a medical AI system is wrong, changes or encounters an unfamiliar case?

The partnership's value depends on who qualifies, how enrollment works and what support remains available after a person closes the app.